List of Livmarli drug patents

Livmarli is owned by Mirum.

Livmarli contains Maralixibat Chloride.

Livmarli has a total of 4 drug patents out of which 0 drug patents have expired.

Livmarli was authorised for market use on 29 September, 2021.

Livmarli is available in solution;oral dosage forms.

Livmarli can be used as treatment of cholestatic pruritus in patients with alagille syndrome (algs).

Drug patent challenges can be filed against Livmarli from September, 2025.

The generics of Livmarli are possible to be released after 12 February, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
May, 2031

(8 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(9 years from now)

US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(17 years from now)

US11497745 MIRUM NA
Feb, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in